Prognostic significance of elevated lactate dehydrogenase and creatine kinase in patients with rhabdomyosarcoma

2003 ◽  
Vol 40 (3) ◽  
pp. 187-188 ◽  
Author(s):  
Hiroshi Moritake ◽  
Sachiyo Kamimura ◽  
Kensuke Akiyoshi ◽  
Yoshihisa Nagatoshi ◽  
Hirokazu Chuman ◽  
...  
Keyword(s):  
Creatine Kinase ◽  
Lactate Dehydrogenase ◽  
Prognostic Significance ◽  
Elevated Lactate ◽  
Elevated Lactate Dehydrogenase

scholarly journals Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution

2018 ◽  
Vol 36 (34) ◽  
pp. 3370-3380 ◽  
Author(s):  
Juan Pablo Alderuccio ◽  
Wei Zhao ◽  
Amrita Desai ◽  
Nicolas Gallastegui ◽  
Jeremy Ramdial ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lactate Dehydrogenase ◽  
Follicular Lymphoma ◽  
Lymphoid Tissue ◽  
Initial Treatment ◽  
Marginal Zone ◽  
Marginal Zone Lymphoma ◽  
Competing Risk ◽  
Elevated Lactate ◽  
Elevated Lactate Dehydrogenase

Purpose Given the paucity of data on higher-grade transformation (HGT) to aggressive lymphoma in patients with marginal zone lymphoma (MZL), we report on a large cohort of patients, identify risk factors, and determine HGT impact on overall survival (OS). Methods We analyzed 453 patients with biopsy-proven MZL seen at our institution between 1995 and 2016. Kaplan-Meier, Cox proportional hazards regression, and competing risk methods were used in analyses of time-to-event outcomes. Results Thirty-four patients (7.5%) had biopsy-proven HGT to diffuse large B-cell lymphoma, including seven (21%) diagnosed at the time of initial MZL diagnosis. Among 27 incident patients, median time to HGT was 29 months (range, 1.3 to 135 months). Higher risk of HGT was observed in those with nodal/splenic MZL (subdistribution hazard ratio [SHR], 2.60; P = .023). On multivariable competing risk analysis, elevated lactate dehydrogenase (SHR, 2.71), more than four nodal sites (SHR, 2.97), and failure to achieve complete remission (CR) after initial treatment (SHR, 3.76) conveyed significantly higher risk for HGT ( P < .02). International Prognostic Index (IPI), Follicular Lymphoma IPI, and Mucosa-Associated Lymphoid Tissue Lymphoma IPI were only significant predictors of HGT univariably. Patients with HGT had shorter OS (5-year rate, 65% v 86%; P < .001). Patients who presented with HGT within 12 months since MZL diagnosis had shorter OS than those with HGT at MZL diagnosis combined with those with HGT more than 12 months later (4-year rate, 43% v 81%, P < .001). Non-CR and higher scores of IPI, Follicular Lymphoma IPI, and Mucosa-Associated Lymphoid Tissue Lymphoma IPI were the main significant predictors for shorter progression-free survival and OS. Conclusion Failure to achieve CR after initial treatment, elevated lactate dehydrogenase, and more than four nodal sites at the time of MZL diagnosis are the main predictors of increased risk of HGT. Patients with HGT have shorter OS.

scholarly journals Moxifloxacin (Avelox) Induced Thrombotic Thrombocytopenic Purpura

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Sikander P. Surana ◽  
Zahily Sardinas ◽  
Alan S. Multz
Keyword(s):  
Renal Failure ◽  
Lactate Dehydrogenase ◽  
Thrombotic Thrombocytopenic Purpura ◽  
African American Female ◽  
Shortness Of Breath ◽  
Laboratory Examination ◽  
Peripheral Smear ◽  
Thrombocytopenic Purpura ◽  
Elevated Lactate ◽  
Elevated Lactate Dehydrogenase

We report a case of a 66-year-old African-American female who presented with complaints of progressively worsening weakness, shortness of breath on minimal exertion, lethargy for the last few days, and short episodes of aphasia lasting 20–30 seconds. Prior to presentation, she was treated with two courses of moxifloxacin for sinusitis. Laboratory examination was remarkable for anemia and thrombocytopenia with elevated lactate dehydrogenase and no evidence of renal failure. Peripheral smear showed numerous schistocytes and she was diagnosed with thrombotic thrombocytopenic purpura. Moxifloxacin was identified as the offending agent. The patient was treated with prednisone and plasmapheresis. To the best of our knowledge, this is the first reported case of thrombotic thrombocytopenic purpura associated with the use of moxifloxacin. Although rare, physicians should be aware of this serious complication associated with its use.

scholarly journals Elevated Lactate Dehydrogenase (LDH) level as an independent risk factor for the severity and mortality of COVID-19

Aging ◽  
2020 ◽  
Vol 12 (15) ◽  
pp. 15670-15681 ◽  
Author(s):  
Chang Li ◽  
Jianfang Ye ◽  
Qijian Chen ◽  
Weihua Hu ◽  
Lingling Wang ◽  
...  
Keyword(s):  
Risk Factor ◽  
Lactate Dehydrogenase ◽  
Independent Risk Factor ◽  
Elevated Lactate ◽  
Elevated Lactate Dehydrogenase

scholarly journals Elevated Levels of Lactate Dehydrogenase Predicts Poor Outcomes for Patients with COVID-19: A Review

2021 ◽  
pp. 139-158
Author(s):  
Dheaa Shamikh Zageer
Keyword(s):  
Lactate Dehydrogenase ◽  
Severe Acute Respiratory Syndrome ◽  
Ldh Release ◽  
Poor Outcomes ◽  
Elevated Lactate ◽  
Elevated Lactate Dehydrogenase

In glucose (Glc) metabolism, lactate dehydrogenase (LDH) functions by changing pyruvate into lactate. Lactate dehydrogenase (LDH) release is induced viacell death, suggesting to disease caused by virus or pulmonary deterioration, such as inflammation of the lung triggered by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). A satisfactory evidence exists by binding elevated lactate dehydrogenase (LDH) levels to the development of coronavirus disease 2019 (COVID-19) complications.

Sign in / Sign up

Export Citation Format

Share Document